ITEMS IN AFP WITH KEYWORD:
Oral bisphosphonates significantly reduce clinical fracture risk at four years in women with postmenopausal osteoporosis (T-score less than −2.5). Treatment beyond five years is associated with further reductions in fractures in women with persistent femoral neck T-scores less than −2.5.
Osteoporosis, which most commonly occurs in the hip, spine, and wrist, puts persons at increased risk of fragility and fracture. The American College of Physicians (ACP) has updated its 2008 guideline to include new evidence regarding fracture prevention in adults with low bone mineral density or osteoporosis.
Vertebral compression fractures can lead to chronic pain, disfigurement, height loss, impaired activities of daily living, increased risk of pressure sores, pneumonia, and psychological distress. Find out which patients are most likely to benefit from conservative therapy, and when to consider surgery.
Review the current recommendations on screening for osteoporosis using dual energy x-ray absorptiometry of the hip and lumbar spine. Nonpharmacologic treatment involves fall prevention strategies, multicomponent exercise programs, and smoking cessation. Bisphosphonates are first-line pharmacologic treatment.
This study found little, if any, additional benefit to repeat BMD screening at four years beyond baseline BMD testing in older men and women. A recent similar study (Gourlay ML, Fine JP, Preisser JS, et al. N Engl J Med. 2012;366(3):225–233) recommended a baseline examination at 65 years of age with...
This practice bulletin from the American College of Obstetricians and Gynecologists (ACOG) reviews diagnosis, evaluation, and treatment options for women with osteoporosis.
In 2007, more than 5.4 million patients in the United States were taking oral bisphosphonates. However, bisphosphonates are under scrutiny because of the risk of bisphosphonate-related osteonecrosis of the jaw.
Prolia is an expensive method of preventing osteoporotic hip fractures, and is associated with significant adverse effects. Safer, less expensive options exist for preventing fracture in high-risk women.
Feb 1, 2012 Issue
Human Parathyroid Hormone for Treating Osteoporosis [FPIN's Clinical Inquiries]
Human parathyroid hormone should be used in patients with severe osteoporosis to decrease the rate of vertebral and nonvertebral fractures.
May 15, 2011 Issue
Screening for Osteoporosis: Recommendation Statement [U.S. Preventive Services Task Force]
The U.S. Preventive Services Task Force (USPSTF) recommends screening for osteoporosis in women 65 years or older and in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman with no additional risk factors.